Pharmacotherapy and mortality in atrial fibrillation-a cohort of men and women 75 years or older in Sweden

Age and Ageing

Volumn 44, Issue 2, 2015, Pages 232-238

  Wändell, Per Erik ^a   Carlsson, Axel Carl ^a,b   Sundquist, Jan ^c,d   Johansson, Sven Erik ^c   Bottai, Matteo ^a   Sundquist, Kristina ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antithrombotic drugs; Mortality; Older people; Propensity score; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DISOPYRAMIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LOOP DIURETIC AGENT; PROPAFENONE; QUINIDINE; THIAZIDE DIURETIC AGENT; ANTIARRHYTHMIC AGENT; CARDIOVASCULAR AGENT; DIURETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHADS2 SCORE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROPENSITY SCORE; SEX DIFFERENCE; SOCIOECONOMICS; SURVIVAL TIME; SWEDEN; VERY ELDERLY; AGE; ATRIAL FIBRILLATION; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; GERIATRIC ASSESSMENT; MORTALITY; MULTICENTER STUDY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; STROKE; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIURETICS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; PROPENSITY SCORE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; STROKE; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925327158     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afu153     Document Type: Article

References (30)

1. Forslund T, Wettermark B, Wandell P, von Euler M, Hasselstrom J, Hjemdahl P. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol 2013; 170: 208-14.
2. Humphries KH, Kerr CR, Connolly SJ et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365-70.
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82(8A): 2N-9N.
4. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: ten years later. Gend Med 2010; 7: 206-17.
5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
6. Larsen TB, Lip GY, Skjoth F, Due KM, Overvad K, Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes 2012; 5: 335-42.
7. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007: CD006186.
8. Orsini N, Wolk A, Bottai M. Evaluating percentiles of survival. Epidemiology 2012; 23: 770-1.
9. Sundquist K, Li X. Coronary heart disease risks in first- and second-generation immigrants in Sweden: a follow-up study. J Intern Med 2006; 259: 418-27.
10. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up. J Hypertens 2007; 25: 1311-7.
11. Carlsson AC, Wandell P, Sundquist K, Johansson SE, Sundquist J. Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. Eur J Clin Pharmacol 2013; 69: 245-53.
12. Bottai M, Zhang J. Laplace regression with censored data. Biom J 2010; 52: 487-503.
13. Dahabreh IJ, Sheldrick RC, Paulus JK et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 2012; 33: 1893-901.
14. Schrier RW, Masoumi A, Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 5: 1132-40.
15. Seeland U, Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handb Exp Pharmacol 2012; 214: 211-36.
16. Ruigomez A, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation. BMC Cardiovasc Disord 2002; 2: 5.
17. Zanchetti A, Julius S, Kjeldsen S et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-8.
18. Costanzo P, Perrone-Filardi P, Petretta M et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens 2009; 27: 1136-51.
19. Shibata MC, Leon H, Chatterley T, Dorgan M, Vandermeer B. Do calcium channel blockers increase the diagnosis of heart failure in patients with hypertension? Am J Cardiol 2010; 106: 228-35.
20. Chen N, Zhou M, Yang M et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010: CD003654.
21. Barsheshet A, Brenyo A, Goldenberg I, Moss AJ. Sex-related differences in patients' responses to heart failure therapy. Nat Rev Cardiol 2012; 9: 234-42.
22. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
23. Gransbo K, Melander O, Wallentin L et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010; 55: 1362-9.
24. Bachmann JM, Majmudar M, Tompkins C, Blumenthal RS, Marine JE. Lipid-altering therapy and atrial fibrillation. Cardiol Rev 2008; 16: 197-204.
25. de Koning JS, Klazinga NS, Koudstaal PJ, Prins A, Borsboom GJMackenbach JP. The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study. BMC Health Serv Res 2005; 5: 10.
26. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004; 94: 889-94.
27. Henriksson KM, Farahmand B, Johansson S, Asberg S, Terent A, Edvardsson N. Survival after stroke--the impact of CHADS2 score and atrial fibrillation. Int J Cardiol 2010; 141: 18-23.
28. Ohlmeier C, Mikolajczyk R, Haverkamp W, Garbe E. Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans. Europace 2013; 10: 1436-44.
29. Sundquist K, Chaikiat A, Leon VR, Johansson SE, Sundquist J. Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Diabetes Metab Res Rev 2011; 27: 244-54.
30. Senn S, Graf E, Caputo A. Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. Stat Med 2007; 26: 5529-44.